Your Health, We Care
Table 7 summarizes drug interactions that affect the exposure of Balversa or serum phosphate level and their clinical management.
Table 8 summarizes the effect of Balversa on other drugs and their clinical management.
from FDA,2024.01
Balversa is specifically designed for patients with advanced urothelial carcinoma, targeting patients with FGFR mutations and bringing new hope to patients by inhibiting cancer cel···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：140
Balversais an oral anti-tumor drug for the treatment of urothelial carcinoma with FGFR2/3 mutations, which blocks tumor growth by inhibiting FGFR activity, but it is necessary to p···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：121
Balversa is a new anti-cancer drug targeting FGFR, targeting urothelial carcinoma with specific gene mutations, accurately blocking tumor growth signals, and bringing new hope to p···【more】
Article source：Lucius LaosRelease date：2024-08-28Recommended：156
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
